Evaluation of glycemic variability with Insulin Aspart (Fiasp) and Insulin Lispro (Lyumjev) for patients with type 1 diabetes mallitus -Prospective observational study-

Evaluation of glycemic variability with Insulin Aspart (Fiasp) and Insulin Lispro (Lyumjev) for patients with type 1 diabetes mallitus -Prospective observational study- - Glycemic variability with Insulin Fiasp and Lyumjev for type 1 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042824

Enrollment

Registered

2020-12-23

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CSII + CGM or sensor augmented pump are used for insulin infusion device and continuous glucose monitoring. Insulin aspart (Fiasp) or insulin lispro (Lyumjev) are or scheduled to initiated.

Exclusion criteria

Exclusion criteria: With pregnancy or lactating

Design outcomes

Primary

Measure	Time frame
Changes in blood glucose variability (including CGM metrics and indicators)	—

Secondary

Measure	Time frame
Relationship between changes in glucose variability and collected data values	—

Countries

Japan

Contacts

Public ContactKyu Yong Cho

Hokkaido University Hospital Internal Medicine 2, Clinical Research and Medical Innovation Center

kyuyong-cho@med.hokudai.ac.jp011-706-1161

Outcome results